Rankings
Publications
Search Publications
Cited-by Search
Sources
Publishers
Scholars
Scholars
Top Cited Scholars
Organizations
About
Scilit
About Us
Advisory Board
Data Sources
Career
Support / Contact
User Guide
Publisher User
Search Function
Rankings Function
API Resource
Scilit Knowledge
Metrics
Scilit Recognitions
Publications Classification
Media
News
Blog
Login
Register
Home
Publications
Supplementary Figure 5 from Farnesyl Transferase Inhibitor KO-2806 (Darlifarnib) Enhances the Antitumor Activity of Tyrosine Kinase Inhibitors in RCC
Home
Publications
Supplementary Figure 5 from Farnesyl Transferase Inhibitor KO-2806 (Darlifarnib) Enhances the Antitumor Activity of Tyrosine Kinase Inhibitors in RCC
Supplementary Figure 5 from Farnesyl Transferase Inhibitor KO-2806 (Darlifarnib) Enhances the Antitumor Activity of Tyrosine Kinase Inhibitors in RCC
Authors:
JG
Jovylyn G. Gasendo
Jovylyn G. Gasendo
SC
Stacia Chan
Stacia Chan
HP
Hetika V. Patel
Hetika V. Patel
AS
Alison E. Smith
Alison E. Smith
LK
Linda Kessler
Linda Kessler
YL
Yahu A. Liu
Yahu A. Liu
AM
Amitava Mitra
Amitava Mitra
FB
Francis Burrows
Francis Burrows
SM
Shivani Malik
Shivani Malik
Article Alert
Citation Alert
Add to Library
Cite
Download
Share
Download
Download PDF
Download
Open Access
Publisher website
Google Scholar
2 September 2026
other
Published by
American Association for Cancer Research (AACR)
DOI:
10.1158/1535-7163.33414216
Abstract
KO-2806 is tolerable in combination with anti-VEGFR TKIs in RCC tumors progressing on TKIs.
Keywords
ANGIOGENESIS
ENDOTHELIAL CELL FUNCTIONS
DRUG RESISTANCE
GENITOURINARY CANCERS
RENAL CANCER
PRECLINICAL MODELS
XENOGRAFT MODELS
Related articles
Scroll to top